Oral contraceptive use and the occurrence of pituitary prolactinoma
- 22 April 1983
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 249 (16) , 2204-2207
- https://doi.org/10.1001/jama.249.16.2204
Abstract
To determine whether prior oral contraceptive (OC) use is a risk factor for pituitary prolactinoma, an attempt was made to identify all women (n = 72) with a prolactinoma diagnosed from 1976-1980 in 3 counties in western Washington [USA]. A control group of 303 women was selected by dialing random telephone numbers from the same counties. Prior OC use, according to OC indication, was ascertained during a standardized telephone interview. Relative to the risk for women who had never used an OC, the risk of prolactinoma for women who had used OC for birth control was 1.3 (95% confidence interval, 0.7-2.6). This risk was 7.7 for women who used OC for menstrual regulation (95% confidence interval, 3.7-17.0). Previous findings of an association between OC use and prolactinoma may have resulted from OC treatment of menstrual irregularity in women with an undiagnosed prolactinoma.This publication has 5 references indexed in Scilit:
- HETEROGENEITY OF PROLACTIN RESPONSES TO OESTRADIOL BENZOATE IN WOMEN WITH PROLACTINOMASThe Lancet, 1981
- Pituitary Adenoma and oral Contraceptives: A Case-Control StudyFertility and Sterility, 1979
- PATHOGENESIS OF PROLACTIN-SECRETING PITUITARY ADENOMASThe Lancet, 1978
- THE DESCRIPTIVE EPIDEMIOLOGY OF PRIMARY INTRACRANIAL NEOPLASMS: THE CONNECTICUT EXPERIENCEAmerican Journal of Epidemiology, 1976
- Neoplasms of the central nervous system.Incidence and population selectivity in the Washington DC, metropolitan areaCancer, 1976